Business
Why Lexicon Pharmaceuticals Stock Doubled and Then Some on Thursday – Motley Fool
The FDA delivered a powerful shot of good news to the company.
What happened
Now this is a stock pop. On Thursday, shares of Lexicon Pharmaceutials(NASDAQ:LXRX) jumped 105% (no, that’s not a typo) after the company issued a major positive regulatory update.
So what
The happy news is that Lexicon’s clinical-stage protein inhibitor sotagliflozin performed well enough in phase 3 clinical trials to support a New Drug Application (NDA) from the Food and Drug Administration. This paves the way for sotagliflozin to win approval for treating patients at risk of heart…
-
Noosa News16 hours agoUnlawful wounding charges, Caloundra – Sunshine Coast
-
General18 hours agoCalifornia worker dead and hundreds arrested after cannabis farm raid
-
Business9 hours agoThis artificial intelligence (AI) and “Magnificent Seven” stock will be the next company to surpass a $3 trillion market cap by the end of 2025
-
General22 hours agoBreaking: Man shot at shopping centre in Sydney's west